2seventy bio (NASDAQ:TSVT) Coverage Initiated by Analysts at The Goldman Sachs Group

Equities researchers at The Goldman Sachs Group started coverage on shares of 2seventy bio (NASDAQ:TSVTGet Rating) in a report issued on Monday, The Fly reports. The firm set a “buy” rating on the stock.

Other research analysts have also issued research reports about the stock. Cowen assumed coverage on shares of 2seventy bio in a research note on Thursday, January 6th. They set an “outperform” rating on the stock. SVB Leerink assumed coverage on shares of 2seventy bio in a research note on Thursday, February 10th. They set an “outperform” rating and a $38.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of 2seventy bio from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Saturday, March 26th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $42.40.

TSVT opened at $13.46 on Monday. 2seventy bio has a fifty-two week low of $11.43 and a fifty-two week high of $64.00. The stock’s 50-day simple moving average is $15.33.

2seventy bio (NASDAQ:TSVTGet Rating) last announced its quarterly earnings results on Tuesday, March 22nd. The company reported ($2.55) EPS for the quarter, beating the consensus estimate of ($2.73) by $0.18. Analysts expect that 2seventy bio will post -5.4 EPS for the current year.

In related news, COO Nicola Heffron sold 1,636 shares of the firm’s stock in a transaction that occurred on Monday, February 7th. The shares were sold at an average price of $16.01, for a total value of $26,192.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

2seventy bio Company Profile (Get Rating)

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.

See Also

The Fly logo

Analyst Recommendations for 2seventy bio (NASDAQ:TSVT)

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.